Daily Pharmacy News

Get your free subscription started now. Just enter your email address below.

Tirzepatide Effects on Cystatin C–Based Kidney Function

In a post hoc comparison with insulin glargine in SURPASS-4 participants with type 2 diabetes and high cardiovascular risk, tirzepatide use slowed the decline of estimated glomerular filtration rates (eGFRs). These results support “a kidney-protective effect” for tirzepatide, the authors conclude.

With a primary outcome of eGFR change from baseline at 52 weeks with pooled tirzepatide (5, 10, and 15 mg) and titrated insulin glargine in adults with type 2 diabetes and high cardiovascular risk, the study showed: “Least squares mean (SE) eGFR-creatinine (mL/min/1.73 m2) changes from baseline with tirzepatide and insulin glargine were −2.5 (0.38) and −3.9 (0.38) (between-group difference, 1.4 [95% CI 0.3–2.4]) and −3.5 (0.37) and −5.3 (0.37) (between-group difference, 1.8 [95% CI 0.8–2.8]) for eGFR-cystatin C. Baseline, 1-year, and 1-year change from baseline values significantly correlated between eGFR-cystatin C and eGFR-creatinine. Measures of eGFR changes did not correlate with body weight changes.”

Source: Diabetes Care